Telix Pharmaceuticals (Innovations) Pty Limited clinical trials
A subsidiary of Telix Pharmaceuticals Limited
The registry lists 24 studies whose lead sponsor is Telix Pharmaceuticals (Innovations) Pty Limited. 9 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 20, 2026.
Status
Registry sponsor names on this page
- Telix Pharmaceuticals (Innovations) Pty Limited21 studies
- Telix Pharmaceuticals (Innovations) Pty Ltd3 studies
Something wrong with this grouping? Tell us on the Telix Pharmaceuticals Limited page.
Studies
Recruiting first, then most recently updated. Showing 24 of 24. All Telix Pharmaceuticals Limited studies →
- Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCCNot yet recruitingNCT07870746Phase 2
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 89Zr-olaratumab Dosimetry in Participants With PDGFR Alpha Positive Solid Tumours and Soft Tissue SarcomaRecruitingNCT06537596Phase 1
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Ltd
- Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent GlioblastomaRecruitingNCT07100730Phase 3
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)RecruitingNCT06520345Phase 3
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone PainRecruitingNCT07197645Phase 1
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCCRecruitingNCT07197580Phase 3
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP StudyRecruitingNCT06750419Phase 3
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese PatientsRecruitingNCT05847348Phase 3
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid TumorsRecruitingNCT05868174Phase 1
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- PSMA PET Combined With MRI for the Detection of PCaActive, not recruitingNCT07052214Phase 3
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)Active, not recruitingNCT05450744Phase 1
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 89Zr-DFO-girentuximab Expanded Access Program (EAP)No longer availableNCT06090331
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 18F-Floretyrosine Expanded Access ProgramNo longer availableNCT06743100
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- [18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related ChangesCompletedNCT07238322
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care OnlyTerminatedNCT04876651Phase 3
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Ltd
- Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging EvaluationsTerminatedNCT06655064
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 89Zr-girentuximab for PET Imaging of CAIX Positive Solid TumorsTerminatedNCT05563272Phase 2
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Ltd
- External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)CompletedNCT05146973Phase 2
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON StudyCompletedNCT03849118Phase 3
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)CompletedNCT04726033Early Phase 1
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry StudyCompletedNCT04786847Phase 1
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell CarcinomaCompletedNCT05861778Phase 1
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 131I-IPA and Concurrent XRT in Recurrent GBMCompletedNCT03849105Phase 1/2
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCCCompletedNCT04496089Phase 1
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited